Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
Public ClinicalTrials.gov record NCT05593328. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil \[5-FU\], and leucovorin (FOLFIRI) and bevacizumab for treatment of confirmed metastatic and/or unresectable colorectal cancer (CRC) in participants with a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation who have progressed on an oxaliplatin/fluoropyrimidinebased regimen in the first-line setting.
Study identification
- NCT ID
- NCT05593328
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 17, 2023 (Actual)
- Primary completion
- Dec 9, 2024 (Actual)
- Completion
- Dec 9, 2024 (Actual)
- Last update posted
- Jan 10, 2025
2023 – 2024
United States locations
- U.S. sites
- 27
- U.S. states
- 16
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona - Phoenix Campus | Phoenix | Arizona | 85054 | — |
| Central Arkansas Radiation Therapy Institute - Cancer Center | Little Rock | Arkansas | 72205-6523 | — |
| Pacific Cancer Medical Center | Anaheim | California | 92801 | — |
| Comprehensive Blood and Cancer Center - Bakersfield | Bakersfield | California | 93309 | — |
| Cancer and Blood Specialty Clinic | Los Alamitos | California | 90720 | — |
| Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| UCI Health - Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| UCLA Health - Santa Monica Parkside Cancer Care | Santa Monica | California | 90404 | — |
| Torrance Memorial Physician Network - Cancer Care and Infusion Center | Torrance | California | 90505 | — |
| PIH Health | Whittier | California | 90602 | — |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | — |
| Memorial Hospital West | Pembroke Pines | Florida | 33028 | — |
| Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion | Grand Rapids | Michigan | 49503 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Washington University School of Medicine Center for Advanced Medicine | St Louis | Missouri | 63110 | — |
| Nebraska Cancer Specialists - Midwest Cancer Center - Legacy | Omaha | Nebraska | 68130 | — |
| Englewood Health | Englewood | New Jersey | 07631 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| Manhattan Hematology Oncology Associates | New York | New York | 10016 | — |
| Gabrail Cancer and Research Center | Canton | Ohio | 44718 | — |
| Trihealth Kenwood | Cincinnati | Ohio | 45236 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| West Cancer Center - East Campus | Germantown | Tennessee | 38138 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
| University of Virginia School of Medicine | Charlottesville | Virginia | 22903 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05593328, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 10, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05593328 live on ClinicalTrials.gov.